If so, then Acorda Therapeutics, Inc. would like you to know that on January 30, 2009, they submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Fampridine-SR, a novel therapy developed to “improve walking ability” in people with multiple sclerosis.
Fampridine-SR is a sustained-release tablet formulation of the investigational drug fampridine (4-aminopyridine or 4-AP). In laboratory studies, fampridine has been found to improve impulse conduction in...
